BBI Brickell Biotech, Inc.

1.55
-0.08  -5%
Previous Close 1.63
Open 1.67
Price To Book 0.66
Market Cap 12,106,554
Shares 7,810,680
Volume 89,110
Short Ratio
Av. Daily Volume 119,664
Stock charts supplied by TradingView

NewsSee all news

  1. Brickell Bio's Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

    BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics

  2. Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics

  3. Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

    NovaQuest temporarily suspended R&D funding payments Brickell filed a motion to dismiss the complaint filed by Bodor Labs and Nicholas S. Bodor in federal court Brickell initiated arbitration proceedings against

  4. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million

  5. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 4Q 2019 with data due 4Q 2020.
Sofpironium Bromide
Axillary hyperhidrosis

Latest News

  1. Brickell Bio's Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

    BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics

  2. Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics

  3. Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

    NovaQuest temporarily suspended R&D funding payments Brickell filed a motion to dismiss the complaint filed by Bodor Labs and Nicholas S. Bodor in federal court Brickell initiated arbitration proceedings against

  4. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million

  5. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million

  6. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million

  7. Hercules Capital Reports Third Quarter 2019 Financial Results

    Achieved Record Net Investment Income of $38.9 Million, or $0.37 per Share, which provides 116% Coverage of Base Distribution Payout Set Record Q3 New Debt and Equity Commitments and Total Fundings of $241.3 Million